Signaling networks assembled by oncogenic EGFR and c-Met

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Solid tumors exhibit variable sensitivity to targeted kinase inhibitors, a phenomenon not fully understood.
• While many tumors express epidermal growth factor receptor (EGFR), only a subset with specific mutations respond to EGFR inhibitors (EGFRIs).
• This suggests responsive tumors have a unique dependence on EGFR signaling for survival, though the mechanisms remain unclear.

Purpose of the Study:

• To investigate the dependence on EGFR signaling in cancer cells.
• To compare signaling networks in non-small-cell lung cancer (NSCLC) cell lines with EGFR-activating mutations versus c-Met amplification.
• To identify key signaling pathways and protein networks involved in drug response.

Main Methods:

• Global proteomic analysis of phospho-tyrosine signaling.
• Comparison of NSCLC cell lines driven by EGFR mutations and c-Met amplification.
• Analysis of receptor tyrosine kinase (RTK) signaling networks.

Main Results:

• Identified an extensive RTK signaling network in cells with activated EGFR or amplified c-Met.
• Demonstrated that targeted tyrosine kinases drive downstream signaling networks in drug-sensitive cells.
• Observed that these extensive networks collapse upon drug treatment.
• Discovered a conserved "core network" of approximately 50 proteins common to both EGFR and c-Met-dependent cells, mediating drug response.

Conclusions:

• Tumor response to targeted kinase inhibitors is linked to a unique dependence on specific signaling pathways.
• An extensive RTK signaling network, including a core set of proteins, is critical for maintaining drug sensitivity.
• Understanding these core networks may reveal new therapeutic strategies for enhancing targeted therapy efficacy in solid tumors.